MA

Mohammed Abdul Qadeer Siddiqui

Active Director Director DIN 11240670
DIN 11240670 First appointment Aug 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Mohammed Abdul Qadeer Siddiqui

Data last updated:

Mohammed Abdul Qadeer Siddiqui is a Director at Anglokind Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11240670
Primary Designation Director
Industry Pharma
First Appointment 13 Aug 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director13 Aug 20252025Active

Board colleagues of Mohammed Abdul Qadeer Siddiqui

NameDINCompanyDesignation
Ali Mohd Siddiqui03561050Anglokind Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Anglokind Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Mohammed Abdul Qadeer Siddiqui

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mohammed Abdul Qadeer Siddiqui

Mohammed Abdul Qadeer Siddiqui currently holds 1 directorship: Anglokind Pharmaceuticals Private Limited (Director, since 13 Aug 2025).

Mohammed Abdul Qadeer Siddiqui was first appointed on 13 Aug 2025 as Director at Anglokind Pharmaceuticals Private Limited.

The current boards of Mohammed Abdul Qadeer Siddiqui's companies include Ali Mohd Siddiqui (Anglokind Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available